

Edgar Filing: Pharma-Bio Serv, Inc. - Form NT 10-K

Pharma-Bio Serv, Inc.
Form NT 10-K
January 31, 2017

OMB APPROVAL
OMB Number: 3235-0058
Expires: October 31, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Estimated average burden
hours per response.....2.50

FORM 12b-25 SEC FILE NUMBER

CUSIP NUMBER
NOTIFICATION OF LATE FILING

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D

For Period Ended: October 31, 2016

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Pharma-Bio Serv, Inc.
Full Name of Registrant

Former Name if Applicable

Pharma-Bio Serv Building, #6 Road 696
Address of Principal Executive Office
(Street and Number)

Dorado, Puerto Rico
City, State and Zip Code

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes

No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Pharma-Bio Serv,
Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 30,
2017

By: /s/ Pedro J. Lasanta

Pedro J. Lasanta
Chief Financial Officer and Vice President of Finance and
Administration
(Principal Financial Officer and Principal Accounting Officer)